Stock News & Analysis

Tilray's stock isn't the bargain it appears to be at first.

The two earlier streaks like it both ended with a down year of over 30%. Is today's run built any differently?

Roberto De Jesus Paris expanded his direct stake by 36%, signaling confidence in the Brazilian bank's equity despite a modest one-year return.

CrowdStrike trades at a steep premium despite ongoing profitability challenges, while UiPath has just turned profitable with a valuation multiple a fraction of its rival's.

Investors should be thinking about monetization strategies.

Shares have moved lower by 3% so far this month.

IHE concentrates 23.6% in Eli Lilly and delivers 1.4% yield, while XPH spreads risk across 62 holdings with a lower 0.35% expense ratio.

SpaceX must prove its AI spending is worth the near-term pain.

Men's Social Security benefits exceed women's at every age, reflecting decades of workforce differences and shaping survivor protections.

Joby's technology impressed, but Wall Street is waiting for revenue.

AMD's net margin doubled while Qualcomm trades at a fraction of its rival's valuation, but customer concentration and competitive threats complicate both bets.

A couple of popular institutional trades are driving much of the purchasing activity.

If I had $10,000 to put into one consumer stock right now, this fast-growing coffee chain would be it, even with real risk attached.

NEAR Protocol is soaring in value this year, but how long can it keep up this performance?

SoundHound's story has changed. The next few quarters should reveal whether its expanded platform can convert greater customer reach into durable growth and stronger economics.

BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly.

Viking's weight loss pill program has a couple of issues, including the fierce competitors who have a big head start.

Bristol Myers Squibb trades at a steeper discount despite higher leverage, while Novo Nordisk commands a premium on exceptional profitability and GLP-1 dominance.

The LEO satellite developer still has plenty of upside potential.

ExxonMobil's pragmatic approach to Venezuela could reward investors, regardless of how much oil the company does or doesn't pump there.